Biogen Pharma (531752)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 5/9 suggests moderate balance sheet health.
• Positive book value per share of ₹0.65 provides a tangible asset floor.
• Trailing profit growth of 248% indicates recent net income improvement, albeit from a minuscule base.
• Low market cap of ₹93 Cr could attract special-situation or restructuring interest.

Concerns

• Zero sales and zero net profit in the latest quarter: no active business.
• ROCE negative at -0.39%, meaning it destroys capital rather than earning a return.
• P/B of 2.15 means paying over twice book value for a 4.5% ROE.
• Promoter holding not disclosed; lack of transparency is a major red flag.

AI Analysis

Let's start with the basics: a business must generate sales. Biogen Pharma reports zero revenue and zero profit in the latest quarter. For a financial service company, that is not a hiccup; it is an absence of operations. The trailing P/E of 24.29 means somebody is marking earnings from a base too tiny to matter. Profit growth of 248% sounds impressive until you see the base is essentially nothing. ROE is 4.5% on a book value of ₹0.65 per share; at ₹1.40, I am paying 2.15 times book for a subpar return. ROCE is negative at -0.39%, so the enterprise doesn't even earn its cost of capital. There is no dividend to compensate, and promoter holding is not disclosed—Benjamin Graham would insist on skin in the game. The 52-week range of ₹0.34 to ₹1.40 shows a quadruple in price, driven likely by speculation, not business growth. With zero sales, no moat exists; there is simply no product or service to defend. The Piotroski score of 5/9 indicates moderate financial health, but that is mathematical trivia when the engine is idle. The PEG ratio of 0.10 is meaningless because the growth rate is an artifact of a low base. This is not an investment; it is a possible turnaround situation or a speculator's lottery ticket. I need evidence of actual revenue, a credible business plan, and management with a track record. Until then, my discipline says 'avoid'.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer